- 15 lug.- 17:40

VALBIOTIS Announces the First Patient First Visit in the International Phase II/III REVERSE-IT Clinical Study on TOTUM-63 to Reduce Type 2 Diabetes Risk Factors

Business Wire.

First development milestone payment of CHF 3 million from Nestlé Health Science

  • The first subject, with fasting hyperglycemia, underwent the initial protocol medical visit prior to randomization at one of the study's clinical investigation centers.
  • The international REVERSE-IT study will include 600 subjects with altered glucose metabolism, spanning from elevated fasting glycemia to early, yet untreated, Type 2 Diabetes. Its primary endpoint is fasting glycemia and it will be led in more than 30 centers in France and abroad.
  • This First Visit of the First Patient triggers a first milestone payment of CHF 3 million from Nestlé Health Science, thereby strengthening VALBIOTIS’ cash position.
- 15 lug.- 17:04

Octapharma Reports Positive Data from octagam® Usage in Critically Ill COVID-19 Patients

Business Wire.

– Study suggests that Intravenous Immunoglobulin (IVIG) Increases Survival in Critically Ill COVID-19 Patients requiring Intubation with Mechanical Ventilation

– Overall survival was 60.8% in the treatment group which received IVIG (octagam® 5%), versus 38.1% in the control group which did not receive IVIG, corresponding to a trend of 2.2 times reduced risk of death when receiving IVIG treatment

– The Effects of IVIG in COVID-19 May Be Related to its Known Immunomodulatory Activities in Various Auto-immune Diseases

- 15 lug.- 15:34

European Commission approves third nintedanib indication in pulmonary fibrosis1

Business Wire.
  • The approval is for the treatment of adults with other chronic fibrosing interstitial lung diseases (ILDs) with a progressive phenotype beyond idiopathic pulmonary fibrosis (IPF).1
  • The decision is based on the results of the INBUILD® trial, the first study to evaluate patients with a broad range of chronic fibrosing interstitial lung diseases (ILDs) and a progressive disease behavior.2
  • Nintedanib is already approved in more than 80 countries for the treatment of idiopathic pulmonary fibrosis (IPF), and for systemic sclerosis-associated interstitial lung disease (SSc-ILD) in more than 40 countries.
- 15 lug.- 04:16

Spotify lanciato in Russia e in altri 12 paesi europei

Business Wire.

Spotify, il servizio di abbonamento per l’ascolto di contenuti in streaming più diffuso al mondo, ora è accessibile ad altre 250 milioni di persone in Europa ed è così presente in 92 paesi

Spotify è disponibile gratuitamente e offre possibilità ineguagliate di scoprire musica personalizzata

Video Economia

Vai alla rubrica Risparmio e Investimenti
Vai al sito: ANSA Professioni


Vai al sito: L'Agenda Economica Finanziaria e Rassegna Stampa dell'ANSA
Vai alla rubrica: Pianeta Camere
Vai alla rubrica: Agrimercati
Vai alla rubrica: PMI

Real Estate

Criptovalute news


Modifica consenso Cookie